Paclitaxel and Celecoxib in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer

Stopped early · Phase 2

Conditions studied: Ovarian Cancer, Primary Peritoneal Cavity Cancer

In brief

RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Celecoxib may stop the growth of cancer by stopping blood flow to the tumor and may increase the effectiveness of paclitaxel by making tumor cells more sensitive to the drug. Giving celecoxib together with paclitaxel may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving paclitaxel together with celecoxib works in treating patients with recurrent or persistent platinum-resistant ovarian epithelial or primary peritoneal cancer.

Key facts

Study ID

NCT00084448

Run by

Gynecologic Oncology Group

Starts

2004-04-01

Last updated by the study team

2013-07-09

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

• Holden Comprehensive Cancer Center at University of Iowa — Iowa City, Iowa, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.